当前位置: 首页 >> 检索结果
201. Association between the interleukin 23 receptor and ankylosing spondylitis is confirmed by a new UK case-control study and meta-analysis of published series.
作者: Tugce Karaderi.;David Harvey.;Claire Farrar.;Louise H Appleton.;Millicent A Stone.;Roger D Sturrock.;Matthew A Brown.;Paul Wordsworth.;Jennifer J Pointon.
来源: Rheumatology (Oxford). 2009年48卷4期386-9页
It has been shown previously that IL-23R variants are associated with AS. We conducted an extended analysis in the UK population and a meta-analysis with the previously published studies, in order to refine these IL-23R associations with AS.
202. Analgesic effects of treatments for non-specific low back pain: a meta-analysis of placebo-controlled randomized trials.
作者: L A C Machado.;S J Kamper.;R D Herbert.;C G Maher.;J H McAuley.
来源: Rheumatology (Oxford). 2009年48卷5期520-7页
Estimates of treatment effects reported in placebo-controlled randomized trials are less subject to bias than those estimates provided by other study designs. The objective of this meta-analysis was to estimate the analgesic effects of treatments for non-specific low back pain reported in placebo-controlled randomized trials.
203. Interleukin-1 promoter region polymorphism role in rheumatoid arthritis: a meta-analysis of IL-1B-511A/G variant reveals association with rheumatoid arthritis.
作者: P Harrison.;J J Pointon.;K Chapman.;A Roddam.;B P Wordsworth.
来源: Rheumatology (Oxford). 2008年47卷12期1768-70页
IL-1 has a central role mediating inflammation and joint destruction in RA. Single nucleotide polymorphisms (SNPs) and haplotype structure in the promoter region can modulate IL-1 function. This study examined the effects of four common promoter SNPs in the IL-1 region on susceptibility and clinical characteristics of RA in British Caucasian patients and assessed the risk of RA by meta-analysis of published studies.
204. The cost-effectiveness of etanercept and infliximab for the treatment of patients with psoriatic arthritis.
作者: Y Bravo Vergel.;N S Hawkins.;K Claxton.;C Asseburg.;S Palmer.;N Woolacott.;I N Bruce.;M J Sculpher.
来源: Rheumatology (Oxford). 2007年46卷11期1729-35页
Tumour necrosis factor (TNF) antagonists have been shown to improve the outcomes in patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA). We assess the cost-effectiveness of two TNF antagonists and so-called 'palliative care' for the treatment of active PsA from the perspective of the UK National Health Service (NHS).
205. Conservative treatments for tennis elbow do subgroups of patients respond differently?
作者: L Bisset.;N Smidt.;D A Van der Windt.;L M Bouter.;G Jull.;P Brooks.;B Vicenzino.
来源: Rheumatology (Oxford). 2007年46卷10期1601-5页
To determine if subgroups of patients with tennis elbow respond differently in treatment.
206. Cost effectiveness of adalimumab for the treatment of ankylosing spondylitis in the United Kingdom.
作者: M F Botteman.;J W Hay.;M P Luo.;A S Curry.;R L Wong.;B A van Hout.
来源: Rheumatology (Oxford). 2007年46卷8期1320-8页
This study evaluated the cost effectiveness of adalimumab vs conventional therapy in patients with active ankylosing spondylitis (AS).
207. The efficacy of inhibiting tumour necrosis factor alpha and interleukin 1 in patients with rheumatoid arthritis: a meta-analysis and adjusted indirect comparisons.
New treatments that inhibit the cytokines tumour necrosis factor alpha (TNFalpha) and interleukin 1 (IL-1) in the treatment of rheumatoid arthritis have proven clinical effect against placebo and methotrexate (MTX) in several clinical trials in early and late-stage disease and different severity groups. Since there are no head-to-head randomized controlled trials directly comparing the currently available treatments, etanercept, adalimumab, infliximab or anakinra, we perform a meta-analysis that adjusts for differences between study characteristics, and allows indirect comparisons between treatments.
208. Combined analysis of three whole genome linkage scans for Ankylosing Spondylitis.
作者: K W Carter.;A Pluzhnikov.;A E Timms.;C Miceli-Richard.;C Bourgain.;B P Wordsworth.;H Jean-Pierre.;N J Cox.;L J Palmer.;M Breban.;J D Reveille.;M A Brown.
来源: Rheumatology (Oxford). 2007年46卷5期763-71页
Ankylosing spondylitis (AS) is a debilitating chronic inflammatory condition with a high degree of familiality (lambda(s) = 82) and heritability (>90%) that primarily affects spinal and sacroiliac joints. Whole genome scans for linkage to AS phenotypes have been conducted, although results have been inconsistent between studies and all have had modest sample sizes. One potential solution to these issues is to combine data from multiple studies in a retrospective meta-analysis.
209. Acupuncture treatment for chronic knee pain: a systematic review.
To evaluate the effects of acupuncture on pain and function in patients with chronic knee pain.
210. Non-Hodgkin's lymphoma--meta-analyses of the effects of corticosteroids and non-steroidal anti-inflammatories.
Recent research has focused on the effects of corticosteroids and non-steroidal anti-inflammatory drugs/agents (NSAIDs) on non-Hodgkin's lymphoma (NHL) risk, with inconclusive results. We conducted meta-analyses of data published to date, to ascertain the over-all association between NHL and corticosteroid use, and between NHL and NSAID use.
211. Acupuncture for peripheral joint osteoarthritis: a systematic review and meta-analysis.
To evaluate the evidence for the effectiveness of acupuncture in peripheral joint osteoarthritis (OA).
212. The PTPN22 C1858T functional polymorphism and autoimmune diseases--a meta-analysis.
作者: Y H Lee.;Y H Rho.;S J Choi.;J D Ji.;G G Song.;S K Nath.;J B Harley.
来源: Rheumatology (Oxford). 2007年46卷1期49-56页
To assess whether combined evidence shows the association between the protein tyrosine phosphatase non-receptor 22 (PTPN22) C1858T polymorphism and autoimmune diseases, and to summarize the effect size of the polymorphism associated with susceptibility of autoimmune diseases.
213. Spa therapy and balneotherapy for treating low back pain: meta-analysis of randomized trials.
Low back pain is a major public health concern and complementary treatments are frequently used for this condition. The objective of this systematic review and meta-analysis was to assess the evidence for or against the effectiveness of spa therapy and balneotherapy for treating low back pain.
214. Association between PADI4 and rheumatoid arthritis: a meta-analysis.
作者: T Iwamoto.;K Ikari.;T Nakamura.;M Kuwahara.;Y Toyama.;T Tomatsu.;S Momohara.;N Kamatani.
来源: Rheumatology (Oxford). 2006年45卷7期804-7页
Polymorphisms and haplotypes of the peptidylarginine deiminase type 4 gene (PADI4) have been reported to be associated with rheumatoid arthritis (RA) in a Japanese population. However, subsequent replication studies showed conflicting results. The aim of this study was to determine whether meta-analysis would prove the existence of the association.
215. Preventing non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: are older strategies more cost-effective in the general population?
作者: R A Elliott.;L Hooper.;K Payne.;T J Brown.;C Roberts.;D Symmons.
来源: Rheumatology (Oxford). 2006年45卷5期606-13页
To assess the relative cost-effectiveness of five gastroprotective strategies for patients in the general population not judged to be at high gastrointestinal (GI) risk requiring regular traditional (t) non-steroidal anti-inflammatory drugs (NSAIDs) for over 3 weeks: tNSAID/H(2) receptor antagonists (H(2)RAs); tNSAID/proton pump inhibitors (PPIs); tNSAID/misoprostol; COX-2 preferential NSAIDs or COX-2-specific NSAIDs (COXIBs).
216. Genome scan meta-analysis of rheumatoid arthritis.
Genome scans for rheumatoid arthritis (RA) have yielded inconsistent results. The absence of replication of linkage might be due to lack of power of individual studies. We performed a genome scan meta-analysis of published data to increase statistical power and to assess evidence for linkage of RA across genome scan studies.
217. A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal.
Combinations of disease-modifying anti-rheumatic drugs (DMARDs) are increasingly used to treat rheumatoid arthritis (RA). Early trials showed their toxicity while recent trials suggest superior efficacy. Trials of DMARD combinations have enrolled different types of patient (early or established RA), used different designs (step-up, parallel or step-down) and utilized a range of outcome measures. We undertook a systematic review of combination DMARD therapy for RA and carried out a meta-analysis to evaluate the evidence for efficacy and toxicity.
218. Leflunomide in rheumatoid arthritis: recommendations through a process of consensus.
作者: P Maddison.;P Kiely.;B Kirkham.;T Lawson.;R Moots.;D Proudfoot.;R Reece.;D Scott.;R Sword.;A Taggart.;C Thwaites.;E Williams.
来源: Rheumatology (Oxford). 2005年44卷3期280-6页
To determine, by consensus, the optimal use of leflunomide in rheumatoid arthritis (RA), using a multidisciplinary panel of experts and performing meta-analyses of available data.
219. Calcium channel blockers for primary Raynaud's phenomenon: a meta-analysis.
To determine the efficacy of calcium channel blockers (CCBs) for primary Raynaud's phenomenon (RP). Primary outcomes were frequency and severity of RP attacks.
220. Improvement in health utility among patients with rheumatoid arthritis treated with adalimumab (a human anti-TNF monoclonal antibody) plus methotrexate.
作者: G W Torrance.;P Tugwell.;S Amorosi.;E Chartash.;N Sengupta.
来源: Rheumatology (Oxford). 2004年43卷6期712-8页
To compare health-related quality of life (HRQoL), as measured by health utility, in patients with rheumatoid arthritis (RA) treated with adalimumab (a human anti-tumour necrosis factor (anti-TNF) monoclonal antibody) plus methotrexate or placebo plus methotrexate.
|